Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hexamethyl Pararosaniline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | TSHR | P16473 | 6/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexamethyl Pararosaniline SCHEMBL30271599 | 0.97 | ALDH1A1 (0.65) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Brilliant Green SCHEMBL608624 | 0.91 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Hydrochloric Acid SCHEMBL453811 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Hydrochloric Acid SCHEMBL21799403 | 0.78 | ALDH1A1 (0.85) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL65261 | 0.78 | ALDH1A1 (1.00) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Hydrochloric Acid SCHEMBL2777835 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Hexamethyl Pararosaniline SCHEMBL21436490 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Brilliant Green SCHEMBL1756300 | 0.76 | HPGD (0.50) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Brilliant Green SCHEMBL2515405 | 0.76 | HPGD (0.50) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| Hydrochloric Acid SCHEMBL2443748 | 0.75 | ALDH1A1 (0.92) | ALDH1A1TSHRALOX15HSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009134794-A1 | MATERIALS AND METHODS FOR CREATING CUSTOMIZED COMPOSITIONS HAVING A TEMPORARY VISUAL INDICATOR | MELKER RICHARD J (US) | 2009-11-05 | — | — | WO | claimed |
| WO-2003022233-A1 | AGENT FOR DYEING KERATIN FIBERS, CONTAINING A BLUE CATIONIC ANTHRAQUINONE DYE | WELLA AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | WO | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4713095-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Chengdu Anticancer Bioscience, Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| EP-4713293-A1 | METAL NANOPARTICLES STABILIZED WITH CATIONIC COMPOUNDS CAPABLE OF ABSORBING VISIBLE LIGHT | Fundació Eurecat (ES) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712944-A1 | TOPICAL PHARMACEUTICAL SKIN COMPOSITION FOR THE DELIVERY OF NITRIC OXIDE IN COMBINATION WITH OTHER TOPICAL DERMATOLOGIC AGENTS | Noxy Health Products, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2025127647-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF CORONAVIRUS INFECTIOUS DISEASE | 연세대학교 산학협력단 | 2025-06-19 | — | — | WO | disclosed |
| US-12325646-B2 | Fertigation water treatment | UNIVERSITY OF GUELPH (CA) | 2025-06-10 | — | — | US | disclosed |
| CN-120044756-A | Photosensitive resin composition | 旭化成株式会社 | 2025-05-27 | — | — | CN | disclosed |
| EP-4305183-B1 | METHODS FOR DELIVERING A CARGO INTO A CELL | Trince bv (BE) | 2025-05-07 | — | — | EP | disclosed |
| CN-119901700-A | Method for measuring chelation and chelation rate of compound amino acid microelement chelate | 湖南德邦生物科技股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-0867171-A2 | Powder composition for the preparation of gels comprising a methyl hydroxyalkyl cellulose | Wella Aktiengesellschaft (DE) | 1998-09-30 | — | — | EP | disclosed |
| WO-1998034618-A1 | COMPOSITION FOR USE AS A FUNGISTAT AND FOR THE TREATMENT OF FUNGAL INFECTIONS | PEACOCK ROBERT (US) | 1998-08-13 | — | — | WO | disclosed |
| US-5789178-A | GENETIC ENGINEERING FOR ANTIINFLAMMATORY AGENTS AND MONOCLONAL ANTIBODIES | CORVAS INTERNATIONAL, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5760052-A | Composition for use as a fungistat and for the treatment of fungal infections | PEACOCK ROBERT (US) | 1998-06-02 | — | — | US | disclosed |
| US-5747296-A | POLYPEPTIDES FOR GENETIC ENGINEERING | CORVAS INTERNATIONAL, INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0682714-A4 | NOVEL NEUTROPHIL INHIBITORS. | CORVAS INT INC (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0682714-A1 | NOVEL NEUTROPHIL INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994014973-A1 | NOVEL NEUTROPHIL INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1994-07-07 | — | — | WO | disclosed |
| US-5240780-A | Pressure sensitive adhesives | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ALDH1A1 568/4885TSHR 4804/4885ALOX15 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.